The drug, developed by Mitsubishi-Tokyo Pharmaceuticals of Japan, is a nucleotide analog pro-drug with potent and selective activity against HBV.
It is currently undergoing phase I human clinical trials.
Its developers say it could prove to be the first curative treatment for HBV infection and may enable patients to undergo shorter courses of treatment than are currently possible.
"It could prove to be the first curative treatment for HBV infection"Gail Cassell.
Under the deal Eli Lilly will have rights to develop and market the drug everywhere, except in Japan.
Eli Lilly vice-president for infectious diseases discovery research, Dr Gail Cassell, said, "We believe Mitsubishi-Tokyo has developed a novel compound that may offer a potential breakthrough for the treatment of hepatitis B."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com